Strategic partnerships Mymetics has a history of collaborations with big players and foundations (Astellas Pharma, PATH-MVI, Gates Foundation), indicating openness to co-development and external validation. This suggests sales opportunities in joint vaccine development programs, sponsored research, or technology licensing dialogues with large biopharma and global health organizations.

Virosome platform leverage The core expertise in virosome-based vaccine delivery and combining fusion viral proteins with designed antigens positions Mymetics to offer its platform for customization against emerging infectious diseases. Sales efforts could focus on providing platform access, antigen pipeline alignment, and contract development services for partner programs seeking thermostable, dose-sparing vaccines.

Thermostable focus Historical emphasis on thermostable, cold-chain independent vaccines highlights a differentiator for global immunization campaigns, especially in low-resource settings. This creates sales opportunities with public health agencies and NGOs prioritizing reliable vaccines that reduce cold-chain logistics and distribution costs.

COVID-19 collaboration Past and ongoing engagement in SARS-CoV-2 virosome vaccine research and preclinical immunogenicity studies implies readiness to engage with customers seeking rapid pandemic-response solutions. Potential sales angles include accelerated development collaborations, co-funding options, or licensing discussions around SARS-CoV-2 related technologies.

Global footprint Presence of a Swiss base with a research lab in the Netherlands and partnerships with international entities indicates a multinational footprint and regulatory familiarity. This can be leveraged to position Mymetics as a globally capable partner for multinational clinical trials, regulatory strategy support, and cross-border vaccine development initiatives.